Rakugi H, Ogihara T
Department of Geriatric Medicine, Osaka University Medical School.
Nihon Rinsho. 1999 May;57(5):1141-7.
Nonpeptide angiotensin II type 1-receptor antagonists, AT1 receptor antagonists, are newly developed and useful drugs for essential hypertension. In Japan, the efficacy and safty of losartan and candesartan cilexetil in patients with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. Both trials revealed that these drugs showed a hypotensive effect comparable to that of enalapril with a high safety since the adverse drug reaction of cough was recognized in very few patients. Since the blood pressure normalizes only in the patient of about 50%, it is often required to add low-dose hydrochlorothiazide or calcium antagonist. Combination therapies further decreased blood pressure without any increases in side effects of the drugs. AT1 receptor antagonists in both mono-therapy and combination therapy with diuretics/Ca antagonists are very useful and safe in the hypertension treatment.
非肽类血管紧张素II 1型受体拮抗剂(AT1受体拮抗剂)是新开发的用于治疗原发性高血压的有效药物。在日本,以马来酸依那普利作为对照药物,通过双盲、平行组比较研究对氯沙坦和坎地沙坦酯在原发性高血压患者中的疗效和安全性进行了评估。两项试验均显示,这些药物的降压效果与依那普利相当,且安全性高,因为很少有患者出现咳嗽这一药物不良反应。由于仅约50%的患者血压恢复正常,因此常常需要加用小剂量氢氯噻嗪或钙拮抗剂。联合治疗可进一步降低血压,且不会增加药物的副作用。AT1受体拮抗剂无论是单药治疗还是与利尿剂/钙拮抗剂联合治疗,在高血压治疗中都非常有效且安全。